Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations

Trial Profile

Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vemurafenib (Primary)
  • Indications Bladder cancer; Cholangiocarcinoma; Chronic lymphocytic leukaemia; Gastrointestinal stromal tumours; Hairy cell leukaemia; Multiple myeloma; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Sarcoma; Thyroid cancer
  • Focus Therapeutic Use
  • Acronyms ACSE
  • Most Recent Events

    • 06 Dec 2023 Planned End Date changed from 1 May 2024 to 1 Dec 2024.
    • 21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress.
    • 01 Feb 2020 Results published in the Annals of Oncology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top